Investing Port

P/E	18.02
P/S	3.5
P/BV	3.75
EV/EBITDA	8.96
EBITDA	0.6045
Цена ао	102.2

		Недооценка Название Значение Оценка P/S 3.5 2 P/BV 3.75 2 P/E 18.02 6 EV/EBITDA 8.96 8	Эффективность Название Значение Оценка ROA, % 11.86 4 ROE, % 24.07 7
	Дивиденды Название Значение Оценка Div yield, % 0 DSI 0 0	Долг Название Значение Оценка Долг/EBITDA 0	Импульс роста Название Значение Оценка Рост прибыли, % 73.01 10 Рост цены акции, % 78.61 10 Рост дивидендов, % 0 0

Название	Год	По итогам периода	Дата закрытия реестра	Дивиденды, %	Дивиденды
Дивиденды	2016	II кв. 2016	01.08.2016	1.49	1.84

Institutions	Объем	Доля, %
BlackRock Fund Advisors	8429383	2.08
AllianceBernstein L.P.	10188705	2.51
BlackRock Asset Management Deutschland AG - ETF	2940447	0.73
Lyxor Funds Solutions S.A.	82529	0.02
Raiffeisen Kapitalanlage GmbH	500307	0.12
DWS Investment S.A. (ETF)	693055	0.17
HSBC Global Asset Management (France)	1973055	0.49
3 Banken-Generali Investment GmbH	668179	0.16
Lyxor International Asset Management S.A.S.	1080962	0.27
Amundi Asset Management	1374911	0.34
UBS Asset Management	11256804	2.78
Sparkasse Oberösterreich Kag MBH	135000	0.03
Invesco Asset Management Ltd	2804507	0.69
Erste Asset Management GmbH	54953	0.01
Caixabank Asset Management SGIIC	916885	0.23
Security Kapitalanlage AG	70411	0.02
East Capital Asset Management S.A.	222300	0.05
JP Morgan Asset Management (UK) Ltd	2155223	0.53
UBS Asset Management (Americas) Inc	864182	0.21
Pioneer Investments Austria GmbH	490776	0.12
T. Rowe Price Associates, Inc.	18676831	4.61
Schroders Investment Mgt North America	4137179	1.02
Fidelity Management & Research Company LLC	17942121	4.42

ETF	Доля, %	Доходность за год, %
ALPS Medical Breakthroughs ETF	3.17	46.02
ETFMG Treatments Testing and Advancements ETF	3.59
iShares MSCI Austria ETF	16.02	18.06

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute\u002Femergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4\u002F7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies\u002Fnon-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.